Corbus Details Full CANYON-1 Data: 5% Weight Loss at 60 mg, Clean Psychiatric Safety
CRBP sits 23% above its 52-week low of $2.81.
Summary
Corbus presented the full CANYON-1 Phase 1b dataset for CRB-913 at ObesityWeek 2026: 5.0% mean weight loss at 60 mg at 12 weeks (p<0.0001 vs placebo), no serious or severe psychiatric events, and 8.3% discontinuation due to adverse events. The company will now take the plan to the FDA.
Key Events · Product Development and Regulatory · CRBP
-
Full CANYON-1 Dose-Response Disclosed
LS mean weight loss at week 12 was 2.8% (20 mg), 3.3% (40 mg) and 5.0% (60 mg) versus 0.0% for placebo, all p<0.0001, with no evidence of plateauing at any dose.
-
Psychiatric Safety Clean at All Doses
No serious or severe treatment-emergent psychiatric AEs and zero suicidality across 188 participants on CRB-913; only one moderate depressive-symptom case, and anxiety ranged 3.1%-8.2%, in line with published GLP-1 data.
-
Tolerability Comparable to GLP-1s
Treatment discontinuation due to AEs was 8.3% overall (21 of 254), and GI events were all mild or moderate with no serious or severe cases; nausea at 60 mg was 22.6% versus 47% for oral semaglutide 25 mg in published data.
-
FDA Engagement Is Next Step
Corbus plans to engage the FDA on the CRB-913 development plan and evaluate combination studies with GLP-1 therapies; no timeline was disclosed.
Analysis · CRBP · Life Sciences
The headline 5% weight-loss figure was already out in September, so the stock-moving question is whether the full dataset holds up — and it does. All three doses beat placebo with p<0.0001, the 60 mg cohort lost 5.0% at 12 weeks with no plateau, and 44.4% of completers at that dose lost at least 5.0%. Just as important for a CB1 drug, the psychiatric profile that sank prior molecules in this class did not appear: zero suicidality, zero severe or serious psychiatric events, and only one moderate depressive-symptom case among 188 treated participants. Discontinuations due to adverse events ran 8.3% overall, in line with GLP-1 benchmarks, and GI events were milder than oral GLP-1 labels. That combination — oral, non-incretin, tolerable — is the whole investment case for CRB-913, and the detail supports it. The company now says it will engage the FDA on the development plan and evaluate GLP-1 combinations, which is the next real checkpoint; no timing was given. Against $115M of cash at September 30 and a widening quarterly loss, the program still needs a partner or fresh capital to reach later-stage trials.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRBP was trading at $3.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69.9M. The 52-week trading range was $2.81 to $12.88. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.